MedTrace Logo

Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma

NCT01334112 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-12-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential role of Axitinib (AG-013736) in the treatment of unresectable/metastatic hepatocellular carcinoma (HCC)

Conditions

Interventions

DRUG

Axitinib (AG-013736)

5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Jennifer Knox, MSc, FRCPC, MD · University Health Network, Princess Margaret Hospital

  • Kelly Burak, MD, FRCPC, BSc, MSc · University of Calgary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01334112 on ClinicalTrials.gov